MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

TransMedics Group Inc

Chiusa

SettoreSettore sanitario

115.83 5.79

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

113.95

Massimo

120.5

Metriche Chiave

By Trading Economics

Entrata

81M

105M

Vendite

17M

161M

P/E

Media del settore

23.277

63.808

Margine di Profitto

65.551

Dipendenti

898

EBITDA

-916K

32M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+33.58% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-686M

3.9B

Apertura precedente

110.04

Chiusura precedente

115.83

Notizie sul Sentiment di mercato

By Acuity

25%

75%

73 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

TransMedics Group Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2025, 19:15 UTC

I principali Market Mover

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Confronto tra pari

Modifica del prezzo

TransMedics Group Inc Previsione

Obiettivo di Prezzo

By TipRanks

33.58% in crescita

Previsioni per 12 mesi

Media 155.1 USD  33.58%

Alto 190 USD

Basso 118 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TransMedics Group Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

8

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

92.43 / 94.18Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

73 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat